Wearable heart-rate monitoring combines different sensors and algorithms to estimate cardiac activity. Consumer wrist devices most often use photoplethysmography (PPG), which measures blood-volume changes under the skin with green or infrared light, while clinical-grade chest straps and single-lead devices use electrocardiography (ECG), which records the heart’s electrical signals directly. Studies and regulatory reviews show that each approach has strengths and limitations that determine accuracy in real-world use.
How accuracy varies by method and context
PPG-based wrist devices are generally accurate for resting heart rate and low-intensity activity, but performance declines during rapid motion, strong perspiration, and irregular rhythms. Research led by Gary Shcherbina at Scripps Translational Science Institute compared several wrist-worn sensors across a range of activities and found that errors increase during high-intensity exercise and when motion artifacts are present. Chest-strap heart-rate monitors using ECG remain the reference for exercise settings because they directly capture cardiac electrical activity and are less susceptible to motion noise. For arrhythmia detection, a major clinical project led by Mintu P. Turakhia at Stanford University, the Apple Heart Study, demonstrated that irregular pulse notifications from a smartwatch could identify atrial fibrillation in some participants, but confirmation with clinical ECG remains essential.
Causes of measurement error and population implications
Key causes of inaccuracy include motion artifact, poor sensor-skin contact, tattoos or heavy wrist hair, ambient temperature, and skin tone. Studies and regulatory statements from the Food and Drug Administration note that PPG signal quality can be reduced in darker skin tones and with certain optical setups, creating potential for unequal performance across populations. Algorithm training and testing datasets that underrepresent diverse users can exacerbate these disparities. The consequence is not only individual measurement error but also potential health inequities if devices systematically underperform for specific groups.
Clinical and social consequences extend beyond measurement precision. False positives from consumer devices can cause anxiety and unnecessary clinic visits; false negatives can delay diagnosis of arrhythmias. Health systems and clinicians face the challenge of integrating wearable data: the American Heart Association recommends cautious interpretation and verification with clinical-grade ECG before making treatment decisions. Data privacy and ownership are additional considerations, as continuous monitoring generates large personal datasets with potential commercial uses.
Manufacturers and researchers are addressing limitations by improving sensor hardware, refining signal-processing algorithms, and validating devices in larger, more diverse cohorts. Continuous ECG-capable wearables with regulatory clearance offer more reliable rhythm assessment for clinical use, while PPG devices remain valuable for trend monitoring, fitness tracking, and prompting clinical evaluation when abnormalities appear. Understanding the trade-offs between convenience and clinical accuracy helps users and clinicians choose the right device and interpret its readings appropriately.